Evotec has bought the German manufacturing operations of Japan’s Central Glass for a nominal €1. The deal is subject to customary closing conditions and is expected to close on 1 November. The business will be renamed Evotec Drug Substance (Germany).
Pharmaceutical CDMO Evotec has acquired GlaxoSmithKline’s site at Verona, Italy, where its Aptuit subsidiary is already active, employing 750. Terms were not disclosed. Following a meeting with site workers, the company has also agreed to rename the site Campus Levi-Montalcini, in honour of the Italian Nobel laureate Rita Levi-Montalcini.
Drug discovery firm Evotec, which also owns the CDMO Aptuit, has acquired the ‘Biopark by Sanofi’ (BBS) operation in Toulouse, France, and will rename it ‘Campus Curie’. The 19 employees are all transferring. Financial terms were not disclosed.
The company said that this acquisition will allow it “to significantly expand its existing capacities at the site over the near to mid-term while retaining maximum flexibility to build up long-term capacity as needed”.
Drug discovery firm Evotec, owner of the API manufacturer Aptuit, is a member of the Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration, which was launched formally on 27 February. This will aim to transform global action on TB, which causes more deaths than any other infectious disease, with 10 million new cases and 1.5 million deaths recorded in 2018.